The molecular bacterial load assay predicts treatment responses in patients with pre-XDR/XDR-tuberculosis more accurately than GeneXpert Ultra MTB/Rif
MBLA was superior in the early identification of successful culture conversion compared to microscopy and Xpert and could be a useful biomarker to evaluate novel entities in Phase IIA early-bactericidal-activity drug trials regardless of the degree of M. tuberculosis drug resistance.
Authors
- Isobella Honeyborne (ORCID: https://orcid.org/0000-0003-0596-758X)
- Jan Heyckendorf (ORCID: https://orcid.org/0000-0003-4203-8421)
- Christoph Lange (ORCID: https://orcid.org/0000-0002-9691-4741)
- Dumitru Chesov (ORCID: https://orcid.org/0000-0001-6203-5020)
- Barbara Kalsdorf
- Antonela Dragomir
- Maja Reimann (ORCID: https://orcid.org/0000-0002-2385-2287)
- Christoph Hölscher
- Oana Popescu
- C Popa
- Alexandra Hölscher
- Marit Neumann
- Roxana Munteanu
Institutions
- Christian-Albrechts-Universität zu Kiel (DE)
- German Center for Infection Research (DE)
- Institutul de Pneumoftiziologie "Marius Nasta" (RO)
- Research Center Borstel - Leibniz Lung Center (DE)
- University College London (GB)
- University of Lübeck (DE)
Publication Details
- Journal
- Journal of Infection
- Published
- 2024-12-27
- DOI
- https://doi.org/10.1016/j.jinf.2024.106399
- Citations
- 10
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 3.89
Funders
- Deutsches Zentrum für Infektionsforschung